Cargando…
NS5A inhibitors unmask differences in functional replicase complex half-life between different hepatitis C virus strains
Hepatitis C virus (HCV) RNA is synthesized by the replicase complex (RC), a macromolecular assembly composed of viral non-structural proteins and cellular co-factors. Inhibitors of the HCV NS5A protein block formation of new RCs but do not affect RNA synthesis by pre-formed RCs. Without new RC forma...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5464671/ https://www.ncbi.nlm.nih.gov/pubmed/28594932 http://dx.doi.org/10.1371/journal.ppat.1006343 |
_version_ | 1783242820188897280 |
---|---|
author | Benzine, Tiffany Brandt, Ryan Lovell, William C. Yamane, Daisuke Neddermann, Petra De Francesco, Raffaele Lemon, Stanley M. Perelson, Alan S. Ke, Ruian McGivern, David R. |
author_facet | Benzine, Tiffany Brandt, Ryan Lovell, William C. Yamane, Daisuke Neddermann, Petra De Francesco, Raffaele Lemon, Stanley M. Perelson, Alan S. Ke, Ruian McGivern, David R. |
author_sort | Benzine, Tiffany |
collection | PubMed |
description | Hepatitis C virus (HCV) RNA is synthesized by the replicase complex (RC), a macromolecular assembly composed of viral non-structural proteins and cellular co-factors. Inhibitors of the HCV NS5A protein block formation of new RCs but do not affect RNA synthesis by pre-formed RCs. Without new RC formation, existing RCs turn over and are eventually lost from the cell. We aimed to use NS5A inhibitors to estimate the half-life of the functional RC of HCV. We compared different cell culture-infectious strains of HCV that may be grouped based on their sensitivity to lipid peroxidation: robustly replicating, lipid peroxidation resistant (LPO(R)) viruses (e.g. JFH-1 or H77D) and more slowly replicating, lipid peroxidation sensitive (LPO(S)) viruses (e.g. H77S.3 and N.2). In luciferase assays, LPO(S) HCV strains declined under NS5A inhibitor therapy with much slower kinetics compared to LPO(R) HCV strains. This difference in rate of decline was not observed for inhibitors of the NS5B RNA-dependent RNA polymerase suggesting that the difference was not simply a consequence of differences in RNA stability. In further analyses, we compared two isoclonal HCV variants: the LPO(S) H77S.3 and the LPO(R) H77D that differ only by 12 amino acids. Differences in rate of decline between H77S.3 and H77D following NS5A inhibitor addition were not due to amino acid sequences in NS5A but rather due to a combination of amino acid differences in the non-structural proteins that make up the HCV RC. Mathematical modeling of intracellular HCV RNA dynamics suggested that differences in RC stability (half-lives of 3.5 and 9.9 hours, for H77D and H77S.3, respectively) are responsible for the different kinetics of antiviral suppression between LPO(S) and LPO(R) viruses. In nascent RNA capture assays, the rate of RNA synthesis decline following NS5A inhibitor addition was significantly faster for H77D compared to H77S.3 indicating different half-lives of functional RCs. |
format | Online Article Text |
id | pubmed-5464671 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-54646712017-06-22 NS5A inhibitors unmask differences in functional replicase complex half-life between different hepatitis C virus strains Benzine, Tiffany Brandt, Ryan Lovell, William C. Yamane, Daisuke Neddermann, Petra De Francesco, Raffaele Lemon, Stanley M. Perelson, Alan S. Ke, Ruian McGivern, David R. PLoS Pathog Research Article Hepatitis C virus (HCV) RNA is synthesized by the replicase complex (RC), a macromolecular assembly composed of viral non-structural proteins and cellular co-factors. Inhibitors of the HCV NS5A protein block formation of new RCs but do not affect RNA synthesis by pre-formed RCs. Without new RC formation, existing RCs turn over and are eventually lost from the cell. We aimed to use NS5A inhibitors to estimate the half-life of the functional RC of HCV. We compared different cell culture-infectious strains of HCV that may be grouped based on their sensitivity to lipid peroxidation: robustly replicating, lipid peroxidation resistant (LPO(R)) viruses (e.g. JFH-1 or H77D) and more slowly replicating, lipid peroxidation sensitive (LPO(S)) viruses (e.g. H77S.3 and N.2). In luciferase assays, LPO(S) HCV strains declined under NS5A inhibitor therapy with much slower kinetics compared to LPO(R) HCV strains. This difference in rate of decline was not observed for inhibitors of the NS5B RNA-dependent RNA polymerase suggesting that the difference was not simply a consequence of differences in RNA stability. In further analyses, we compared two isoclonal HCV variants: the LPO(S) H77S.3 and the LPO(R) H77D that differ only by 12 amino acids. Differences in rate of decline between H77S.3 and H77D following NS5A inhibitor addition were not due to amino acid sequences in NS5A but rather due to a combination of amino acid differences in the non-structural proteins that make up the HCV RC. Mathematical modeling of intracellular HCV RNA dynamics suggested that differences in RC stability (half-lives of 3.5 and 9.9 hours, for H77D and H77S.3, respectively) are responsible for the different kinetics of antiviral suppression between LPO(S) and LPO(R) viruses. In nascent RNA capture assays, the rate of RNA synthesis decline following NS5A inhibitor addition was significantly faster for H77D compared to H77S.3 indicating different half-lives of functional RCs. Public Library of Science 2017-06-08 /pmc/articles/PMC5464671/ /pubmed/28594932 http://dx.doi.org/10.1371/journal.ppat.1006343 Text en https://creativecommons.org/publicdomain/zero/1.0/ This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 (https://creativecommons.org/publicdomain/zero/1.0/) public domain dedication. |
spellingShingle | Research Article Benzine, Tiffany Brandt, Ryan Lovell, William C. Yamane, Daisuke Neddermann, Petra De Francesco, Raffaele Lemon, Stanley M. Perelson, Alan S. Ke, Ruian McGivern, David R. NS5A inhibitors unmask differences in functional replicase complex half-life between different hepatitis C virus strains |
title | NS5A inhibitors unmask differences in functional replicase complex half-life between different hepatitis C virus strains |
title_full | NS5A inhibitors unmask differences in functional replicase complex half-life between different hepatitis C virus strains |
title_fullStr | NS5A inhibitors unmask differences in functional replicase complex half-life between different hepatitis C virus strains |
title_full_unstemmed | NS5A inhibitors unmask differences in functional replicase complex half-life between different hepatitis C virus strains |
title_short | NS5A inhibitors unmask differences in functional replicase complex half-life between different hepatitis C virus strains |
title_sort | ns5a inhibitors unmask differences in functional replicase complex half-life between different hepatitis c virus strains |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5464671/ https://www.ncbi.nlm.nih.gov/pubmed/28594932 http://dx.doi.org/10.1371/journal.ppat.1006343 |
work_keys_str_mv | AT benzinetiffany ns5ainhibitorsunmaskdifferencesinfunctionalreplicasecomplexhalflifebetweendifferenthepatitiscvirusstrains AT brandtryan ns5ainhibitorsunmaskdifferencesinfunctionalreplicasecomplexhalflifebetweendifferenthepatitiscvirusstrains AT lovellwilliamc ns5ainhibitorsunmaskdifferencesinfunctionalreplicasecomplexhalflifebetweendifferenthepatitiscvirusstrains AT yamanedaisuke ns5ainhibitorsunmaskdifferencesinfunctionalreplicasecomplexhalflifebetweendifferenthepatitiscvirusstrains AT neddermannpetra ns5ainhibitorsunmaskdifferencesinfunctionalreplicasecomplexhalflifebetweendifferenthepatitiscvirusstrains AT defrancescoraffaele ns5ainhibitorsunmaskdifferencesinfunctionalreplicasecomplexhalflifebetweendifferenthepatitiscvirusstrains AT lemonstanleym ns5ainhibitorsunmaskdifferencesinfunctionalreplicasecomplexhalflifebetweendifferenthepatitiscvirusstrains AT perelsonalans ns5ainhibitorsunmaskdifferencesinfunctionalreplicasecomplexhalflifebetweendifferenthepatitiscvirusstrains AT keruian ns5ainhibitorsunmaskdifferencesinfunctionalreplicasecomplexhalflifebetweendifferenthepatitiscvirusstrains AT mcgiverndavidr ns5ainhibitorsunmaskdifferencesinfunctionalreplicasecomplexhalflifebetweendifferenthepatitiscvirusstrains |